All News

The continued approval for this indication may be subject upon verification and description of clinical benefit in a confirmatory trial.

Approved by the FDA on June 29, 2020, the pertuzumab, trastuzumab, and hyaluronidase-zzxf combination therapy with chemotherapy offers several advantages to the standard treatment of pertuzumab plus trastuzumab with chemotherapy for breast cancers with HER2 overexpression.

These findings could lead to improved therapies and prolonged survival for patients with metastatic TNBC, according to the study authors.

New roles and responsibilities can be passed to pharmacy technicians in order to free up pharmacists’ time, which enables them to be more engaged with their patients and provide more direct patient care.

English discussed the challenges and highlights of her time in the trial, in addition to what she feels health care professionals should learn from her own treatment experience.

Dennis Wright, senior director of product marketing for Central Pharmacy Compounding and Dispensing at Omnicell, discusses methods of addressing the rising rate of hospital pharmacist burnout through automation and technology-enabled services.

What many preceptors may not realize is that in addition to learning about practice settings, all graduates of pharmacy schools in the United States must also be able to demonstrate leadership, innovation, and entrepreneurship.

Amesh Adalja, MD, FIDSA, FACP, FACEP, said that the efficacy of COVID-19 booster vaccines against variants of concern is still relatively unknown, although administering the third shots does increase antibodies as expected.

Ten quiz questions to assess your knowledge on common dyslipidemia treatments.

Non-alcoholic steatohepatitis is the most severe form of non-alcoholic fatty liver disease.

Semaglutide is a once weekly subcutaneous injection that was granted FDA approval for use in adults with obesity or overweight with at least one other weight related-condition.

COVID-19 vaccination opportunities will likely be present for years to come.

The FDA has approved Qelbree (viloxazine extended-release capsules; Supernus Pharmaceuticals, Inc) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in pediatric patients aged 6 to 17 years.

Alembic Pharmaceuticals, Inc in Bridgewater, NJ is a subsidiary of Alembic Pharmaceuticals Ltd., the oldest pharmaceutical company in India, employing more than 12,000 people.

Atrial fibrillation, bleeding, infection, and other adverse events may occur with this therapy.

This has caused an ongoing problem with mistrust in many vaccines and medications, since there is still uncertainty surrounding how they affect other races and ethnicities.

In the fifth part of the series, students discussed the effects the pandemic had on their future career goals or prospects.

Specific infection-fighting cells of the immune system found to be downregulated, offering a potential clue to the cause of prolonged COVID-19 illness in children.

The FDA has granted orphan drug designation to CFT7455 for the treatment of multiple myeloma, according to a press release from manufacturer C4 Therapeutics.

The designation highlights the need for new treatment options for patients with platinum-resistant ovarian cancer and the significant treatment potential of IN10018, according to a press release from InxMed, the manufacturer of the novel drug.

An announcement from CDC officials recommending COVID-19 boosters for all adults could come as soon as this week, although doses would only be widely administered once the FDA formally approved the vaccines.

Ridinilazole is not currently approved for use by any regulatory authority.

Physicians may ask for either or both of comprehensive metabolic panel or complete blood count tests every 3 to 6 months, based on the conditions patients have.

Savings for these medications range from 40% to 75.8%, study results show.

Ticovac is the only FDA-approved vaccine against the TBE virus for individuals visiting or living in TBE endemic areas.

It is time to standardize to a single formulation to avoid mix-ups that can lead to adverse effects.

The expanded indication follows Lyumjev’s original approval in 2020 and offers an important new delivery mechanism for patients with diabetes.

The approval marks the first HIF-2α inhibitor therapy approved in the United States for some types of Von Hippel-Lindau disease-associated tumors.